Mass Tort brief
Chemical liability maneuvers meet escalating product injury dockets
State attorneys move to freeze a $22 billion corporate spinoff over PFAS liabilities as GLP-1 blindness claims and cosmetics cancer dockets mount.
Mass Tort
Twenty states moved to freeze Corteva's $22B seed spinoff — refusing to let chemical makers isolate profitable assets while dumping toxic PFAS liabilities.
BackgroundAqueous film-forming foams containing per- and polyfluoroalkyl substances, or PFAS, were used for decades in industrial and military firefighting operations. Multidistrict litigation in South Carolina coordinates municipal and state environmental contamination claims against major chemical producers.
- California AG Rob Bonta led the multi-state filing seeking an emergency freeze on $22 billion in commercial agricultural seed assets ahead of the transaction.
- State prosecutors allege the planned spinoff to a new entity named Vylor leaves Corteva undercapitalized to satisfy eventual toxic water remediation judgments.
- The motion targets corporate maneuvers that isolate valuable operating divisions while isolating toxic chemical liabilities in separate corporate entities, imperiling state cleanup funds.
Mass Tort
The chemical hair relaxer docket reached 12,000 cases ahead of Daubert hearings — the upcoming scientific rulings will determine whether cosmetics makers face multi-billion dollar trials.
BackgroundDaubert hearings allow federal trial judges to evaluate the scientific validity and methodology of expert witness testimony before it is presented to juries. Cosmetics manufacturers have long incorporated phthalates and endocrine disruptors into cosmetic hair-straightening formulas marketed widely across the country.
- Plaintiffs, primarily Black women, allege long-term exposure to cosmetic relaxers caused uterine, endometrial, and ovarian tumors, demanding medical monitoring and compensatory damages.
- Parties filed dispositive summary judgment briefs and expert witness challenge filings before federal judge Mary Rowland in Chicago to test epidemiological links.
- Initial bellwether personal injury trials are scheduled for early 2027, establishing baseline settlement valuation ranges across the cosmetics industry.
Mass Tort
GLP-1 lawsuits expanded to permanent optic nerve blindness — introducing a devastating physical injury that sharply elevates settlement liabilities for Novo and Lilly.
BackgroundMultidistrict litigation coordinates hundreds of separate personal injury claims before a single federal judge to streamline pretrial evidence discovery. Thousands of plaintiffs have previously sued GLP-1 makers alleging gastroparesis and stomach paralysis after using Ozempic, Wegovy, or Mounjaro.
- Federal NAION vision-loss lawsuits were consolidated into MDL 3163 in Pennsylvania, opening a second major personal injury track alongside stomach-paralysis claims.
- Plaintiffs allege pharmaceutical manufacturers failed to update drug safety labels despite clinical studies highlighting ischemic optic neuropathy risks, leaving doctors unwarned.
- The litigation challenges blockbuster revenue growth across Ozempic, Wegovy, and Mounjaro as personal injury dockets expand into severe permanent disabilities.
Mass Tort
Sandoz opened final claims on a $275M price-fixing settlement — concluding over a decade of litigation over generic drug market allocation.
BackgroundMultidistrict antitrust litigation consolidated dozens of private and state lawsuits accusing major generic drug manufacturers of colluding to inflate medication prices. Settlement funds compensate consumers, commercial health insurance funds, and municipal employee benefit trusts that overpaid for generic prescriptions.
- The approved settlement compensates consumer classes and commercial health insurers who reimbursed inflated generic drug prescriptions between 2009 and 2019.
- The litigation centered on direct communications between generic pharmaceutical executives to allocate customer accounts and avoid competitive discounting on dozens of common treatments.
- Class claimants face an official deadline of November 9, 2026 to submit reimbursement filings to the court-appointed administrator for final payouts.
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
